undamentalytics Newsletter

ResMed| dividend history

ResMed|'s dividend was $2.40 a share in fiscal 2026, up 13.2% on the year before. That was 23.0% of net income. It has raised its dividend per share every year since fiscal 2022.

Dividends, buybacks and capital spending

FY2027 Q1 TTM
Buybacks (TTM)
$1.5B
Dividends (TTM)
$357M
Returned to shareholders
115%
of free cash flow
Buybacks, last 3 fiscal years
$1.2B
Diluted share count
−1.3%
year over year
Total shareholder yield
5.6%
dividends 1.1% + buybacks 4.5% of market value
Dividend payout ratio
22%
of net income paid out
R&D spending
6.9%
of revenue
Sales & admin spending
20.5%
of revenue
Days sales outstanding
62 days
receivables vs revenue

Dividends by fiscal year

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

ResMed|: dividends by fiscal year, annual
Fiscal year2010Jun 20102011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026LTMSept 2026
Dividend per share———$0.680$1.00$1.12$1.20$1.32$1.40$1.48$1.56—$1.68$1.76$1.92$2.12$2.40—
Dividend per share growth————+47.1%+12.0%+7.1%+10.0%+6.1%+5.7%+5.4%——+4.8%+9.1%+10.4%+13.2%—
Dividends paid———97142157168186199212225227245258282311350357
Share buybacks131163393186202160102—5423——001503007001,486
Dividends ÷ net income———31.6%41.0%44.6%47.7%54.4%63.2%52.3%36.2%47.8%31.5%28.8%27.7%22.2%23.0%22.4%

Dividend per share is the amount declared for the fiscal year as stated in the company's filings (including any special dividend), restated for stock splits and checked against the cash dividends paid. Dividends paid and buybacks are cash amounts; the last-twelve-months column can include an extra payment when a quarter-end date moves.

Compare with peers

Head to head: RMD vs STE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from ResMed|'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ResMed|.